1 week Ago By Defense World Staff
JPMorgan Chase & Co. increased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by 4.
9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,250,656 shares of the company’s stock after acquiring an additional 200,411 shares during the period. JPMorgan Chase & Co.
owned about 1.68% of Maravai LifeSciences worth $23,166,000 as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds have also added to or reduced their stakes in MRVI.
Jennison Associates LLC boosted its holdings in shares of Maravai LifeSciences by 0.3% in the 4th quarter. Jennison Associates LLC now owns 2,990,414 shares of the company’s stock valued at $16,298,000 after purchasing an additional 9,769 shares in the last quarter.
Geode Capital Management LLC grew its position in Maravai LifeSciences by 6.3% in the third quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock valued at $22,874,000 after acquiring an additional 162,601 shares during the last quarter.
Pier Capital LLC raised its stake in Maravai LifeSciences by 137.0% during the fourth quarter. Pier Capital LLC now owns 1,127,773 shares of the company’s stock worth $6,146,000 after acquiring an additional 651,921 shares in the last quarter.
Royce & Associates LP lifted its holdings in shares of Maravai LifeSciences by 5.5% in the fourth quarter. Royce & Associates LP now owns 958,885 shares of the company’s stock worth $5,226,000 after acquiring an additional 50,107 shares during the last quarter.
Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Maravai LifeSciences by 6.3% in the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 946,576 shares of the company’s stock valued at $7,866,000 after purchasing an additional 56,071 shares in the last quarter. 50.
25% of the stock is owned by institutional investors. Maravai LifeSciences Stock PerformanceNASDAQ MRVI opened at $1.94 on Thursday.
The company has a 50-day simple moving average of $3.08 and a two-hundred day simple moving average of $5.14.
Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.74 and a 12-month high of $11.
56. The firm has a market cap of $493.41 million, a price-to-earnings ratio of -1.
18 and a beta of 0.18. The company has a quick ratio of 9.
94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89.
Insider ActivityIn other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.
00. Following the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at $843,118.54.
The trade was a 12.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
0.63% of the stock is currently owned by corporate insiders. Analysts Set New Price TargetsMRVI has been the topic of a number of research reports.
Robert W. Baird cut shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $3.
00 in a research note on Wednesday, February 26th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research report on Friday, March 21st.
Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating on the stock. Bank of America lowered their price objective on Maravai LifeSciences from $9.
00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Finally, UBS Group cut their target price on shares of Maravai LifeSciences from $8.
00 to $2.50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company.
Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.31.Read Our Latest Stock Report on Maravai LifeSciencesAbout Maravai LifeSciences (Free Report)Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.See AlsoFive stocks we like better than Maravai LifeSciencesCanada Bond Market Holiday: How to Invest and Trade Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreBreakout Stocks: What They Are and How to Identify ThemAre Tariffs Threatening Disney’s Comeback Story?How to Find Undervalued StocksIs Alphabet a Generational Buying Opportunity at These Levels?Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report)..
